Article

A prospective study of the risk of transfusion-acquired viral infections.

Department of Laboratory Medicine, University of California San Francisco 94143-0884, USA.
Transfusion Medicine (Impact Factor: 1.31). 10/1998; 8(3):173-8. DOI: 10.1046/j.1365-3148.1998.00148.x
Source: PubMed

ABSTRACT The risk of transfusion-transmitted viral infections may be estimated by several methods, but only prospective studies of transfusion recipients can directly measure the incidence, with associated 95% upper confidence bound, of these infections. From 1989 through 1995, 764 recipients of allogeneic or autologous red blood cell transfusions were enrolled; 486 (64%) provided both pretransfusion and 6-month follow-up specimens. Both specimens were tested for anti-HBc, anti-HCV, anti-HTLV-I and anti-HIV, with appropriate confirmatory testing. Thirty-nine (8.0%) subjects had seroprevalent anti-HBc, 19 (3.9%) subjects had seroprevalent anti-HCV, three (0.6%) subjects had seroprevalent anti-HTLV-I/II, and one (0.2%) subject had seroprevalent anti-HIV. There were no seroconversions for any agent among the 34 patients who received only autologous blood, and no confirmed seroconversions for anti-HTLV-I or anti-HIV among all subjects. There were three seroconversions for anti-HBc (incidence 1.04 x 10(-3); 95% confidence interval (CI) 2.15 x 10(-4), 3.05 x 10(-3) per allogeneic unit transfused), and two confirmed seroconversions for HCV (incidence 6.94 x 10(-4); 95% CI 8.34 x 10(-5), 2.51 x 10(-3) per allogeneic unit transfused). One of the two anti-HCV seroconversions occurred in March 1994, after the institution of HCV EIA 2.0 screening of donated blood. Transfusion-associated seroconversions to hepatitis B and C markers were observed at low rates in the early 1990s despite testing donors for markers of both viruses, whereas seroconversions to HTLV-I or HIV were less than 1.04 x 10(3) per allogeneic unit transfused, based upon the upper 95% confidence interval of the zero incidence in this study.

0 Followers
 · 
45 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human T-cell lymphotropic virus type 1 (HTLV-1), the first human retrovirus discovered, has a tropism for T lymphocytes and has been established as the causative agent of adult T-cell leukemia/lymphoma (ATLL), an aggressive CD4 T-cell malignancy (1–4). HTLV-2 was subsequently isolated and found to share approximately 60% nucleotide sequence homology with HTLV-1 (5). In the mid-1980s, HTLV-1 began to be associated through epidemiologic studies as a contributing factor in chronic neurodegenerative disorders. These clinical syndromes were first reported in Japan and Martinique (French West Indies), both regions that were endemic for HTLV-1 infection (6,7). Through important international cooperative studies, both syndromes were revealed to be identical in clinical presentation and are now known collectively as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-2 has been sporadically associated with lymphoproliferative diseases and recently has been implicated in isolated case reports of neurological disease (8,9).
    10/2007: pages 319-336;
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: Retrovirus-derived vectors provide efficient means of gene-transfer and are potential tools for therapeutic intervention against congenital or inherited disorders by in-utero gene therapy and for gene-transfer into dividing cells both in vitro and in vivo. To improve biodistribution of retroviral gene-transfer vectors and to obtain efficient gene-transfer towards hematopoietic stem cells via pre-natal administration, we performed in-utero administration of retroviral vectors pseudotyped with different envelope glycoproteins. Relatively high gene-transfer was obtained with significant differences in biodistribution and gene-transfer efficiency using various pseudotypes. There was significant reduction in the percentage of colonies containing transgene, 3 months postnatally. Next, we used HIV-derived lentiviral vectors to investigate the role of human T-lymphotropic virus type-1 (HTLV-1) accessory protein p12(I) in viral pathogenesis. HTLV-1, a deltaretrovirus cause adult T-cell leukemia/lymphoma, and other lymphocyte-mediated disorders. HTLV-1 provirus encodes various regulatory and accessory genes, including ORF-I encoded p12(I). We have demonstrated that this endoplasmic reticulum-localizing protein, increases intracellular calcium, activates NFAT-mediated transcription and is critical for infectivity in vivo and in vitro. Herein, using microarrays, we tested the role of p12(I) in regulating cellular gene expression in T-lymphocytes and found that p12(I) altered the expression of several calcium-regulated genes and genes associated with T-cell signaling, cell-proliferation and apoptosis. Furthermore, p12(I) upregulated the levels of p300 to transcriptionally significant levels, in T-lymphocytes. Next, we further characterized the mechanism of p300 upregulation by p12(I) and demonstrate that it is calcium-dependent, but calcineurin-independent. Sustained low-magnitude calcium release results in increased p300 RNA, protein and p300-mediated transcriptional activity in T-lymphocytes. Calcium-responsive p300-mediated transcription was inhibited by the p300-binding protein, adenovirus E1A, but not by p300-binding deficient E1A mutant. Additionally, ER localization of p12(I) is required for enhancing p300 levels. Collectively, our data indicate that retroviral vectors can be improved to provide effective tools for gene delivery. Using this approach, we found that HTLV-1 p12(I) modulates cellular gene expression to facilitate T-lymphocyte activation and enhances the expression of a rate-limiting co-adaptor p300 in a calcium-dependent manner. These findings provide valuable insights into the mechanisms of HTLV-1 mediated T-lymphocyte proliferation to enhance viral infectivity and clonal expansion of its genome during cell division. Title from first page of PDF file. Document formatted into pages; contains xvii, 279 p.; also includes graphics (some col.) Thesis (Ph. D.)--Ohio State University, 2004. Includes bibliographical references (p. 237-279). System requirements: World Wide Web browser and PDF viewer.